Xinmao Song1, Jie Wang2, Shengzi Wang3, Weifang Wang1, Shuyi Wang4, Wenjia Zhu2. 1. Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of FuDan University, Fenyang Road 83, Shanghai, 200031, China. 2. Department of E.N.T., Eye, Ear, Nose & Throat Hospital of FuDan University, Fenyang Road 83, Shanghai, 200031, China. 3. Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of FuDan University, Fenyang Road 83, Shanghai, 200031, China. shengziwang@fudan.edu.cn. 4. Department of Clinical Pathology, Eye, Ear, Nose & Throat Hospital of FuDan University, Fenyang Road 83, Shanghai, 200031, China.
Abstract
PURPOSE: To investigate the pathology, clinical manifestations, and potential risk factors associated with the prognosis of malignant lacrimal sac tumors. In addition, the treatment outcomes and complications were also evaluated. METHODS: Ninety cases of malignant lacrimal sac tumors were retrospectively analyzed at our hospital. Pathological classifications, clinical manifestations, risk factors, and follow-up time were documented. The outcomes and complications were evaluated and compared among the various treatment modalities. RESULTS: The median follow-up time was 50 months (range, 3-258 months). The 5-year overall survival (OS) and progression-free survival (PFS) for all cases were 85.7 and 77.9%, respectively. The 5-year OS and PFS for 69 cases of squamous cell carcinoma were 87.6 and 76.3%, and which were 80.4 and 72.4% for 21 cases of non-squamous cell carcinoma, respectively. There was no difference of 5-year OS and PFS between squamous cell carcinoma and non-squamous cell carcinoma (p = 0.350 and p = 0.946). Positive lymph node status was associated with worse OS (p < 0.001) and PFS (p = 0.020). For the 23.3% of cases (21/90) treated with the definitive radiotherapy, the outcomes were equivalent to that of surgery combined with radiotherapy, with the incidence of treatment-related visual acuity complication not being significant. The addition of chemotherapy to the treatment course had a marginal and non-significant improvement in OS and distant metastasis-free survival. CONCLUSIONS: Lymph node status was found to be a key factor for prognosis. Advanced tumors could benefit from multimodality treatment, with radiotherapy playing an important role. However, the role of chemotherapy requires further investigation.
PURPOSE: To investigate the pathology, clinical manifestations, and potential risk factors associated with the prognosis of malignant lacrimal sac tumors. In addition, the treatment outcomes and complications were also evaluated. METHODS: Ninety cases of malignant lacrimal sac tumors were retrospectively analyzed at our hospital. Pathological classifications, clinical manifestations, risk factors, and follow-up time were documented. The outcomes and complications were evaluated and compared among the various treatment modalities. RESULTS: The median follow-up time was 50 months (range, 3-258 months). The 5-year overall survival (OS) and progression-free survival (PFS) for all cases were 85.7 and 77.9%, respectively. The 5-year OS and PFS for 69 cases of squamous cell carcinoma were 87.6 and 76.3%, and which were 80.4 and 72.4% for 21 cases of non-squamous cell carcinoma, respectively. There was no difference of 5-year OS and PFS between squamous cell carcinoma and non-squamous cell carcinoma (p = 0.350 and p = 0.946). Positive lymph node status was associated with worse OS (p < 0.001) and PFS (p = 0.020). For the 23.3% of cases (21/90) treated with the definitive radiotherapy, the outcomes were equivalent to that of surgery combined with radiotherapy, with the incidence of treatment-related visual acuity complication not being significant. The addition of chemotherapy to the treatment course had a marginal and non-significant improvement in OS and distant metastasis-free survival. CONCLUSIONS: Lymph node status was found to be a key factor for prognosis. Advanced tumors could benefit from multimodality treatment, with radiotherapy playing an important role. However, the role of chemotherapy requires further investigation.
Authors: A Montalban; B Liétin; C Louvrier; M Russier; J-L Kemeny; T Mom; L Gilain Journal: Eur Ann Otorhinolaryngol Head Neck Dis Date: 2010-10-29 Impact factor: 2.080
Authors: L D Sjö; E Ralfkiaer; B R Juhl; J U Prause; T Kivelä; C Auw-Haedrich; F Bacin; M Carrera; S E Coupland; B Delbosc; N Ducrey; B Kantelip; J L Kemeny; P Meyer; N C Sjö; S Heegaard Journal: Br J Ophthalmol Date: 2006-05-03 Impact factor: 4.638